Gilead Sciences' recent Q2 2026 earnings call centered on three near-term binary events — an FDA decision on bictegravir plus lenacapavir (BIC/LEN) due by August 27, a December 23 PDUFA date for anito-cel in multiple myeloma, and Phase III data supporting a 2027 launch for the once-weekly oral HIV regimen islatravir plus lenacapavir (ISL/LEN) — while Chief Medical Officer Dietmar Berger disclosed that GS-1720 has received FDA clearance to advance into Phase II, enabling two parallel wholly-owned once-weekly oral HIV programs to move forward simultaneously.
Gilead Sciences' Q2 2026 earnings call highlighted three near-term pipeline catalysts: an August 27 FDA decision on bictegravir plus lenacapavir (BIC/LEN), a December 23 PDUFA date for anitocabtagene autoleucel (anito-cel), and plans for a 2027 launch of the once-weekly oral HIV regimen islatravir plus lenacapavir (ISL/LEN). Management also disclosed that GS-1720 has received FDA clearance to advance into Phase II, expanding Gilead's wholly owned once-weekly oral HIV pipeline.
Total product sales reached USD 7.6 billion for the quarter, up 8% year-on-year, with base business sales (excluding Veklury) growing 10%; Gilead raised full-year base business sales guidance to USD 29.8 billion to USD 30.1 billion.
Key Strategic Signals
BIC/LEN FDA decision by August 27 — first dedicated switch regimen in Gilead's treatment portfolio: Berger confirmed the FDA has granted bictegravir/lenacapavir priority review, with a decision expected by August 27. Management said the once-daily single-tablet combination of two orthogonal mechanisms — integrase inhibition and capsid inhibition — is intended specifically for virally suppressed patients switching from existing regimens, a segment where Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) already holds a dominant position. Management said the regimen is intended for virally suppressed patients switching from existing therapy, expanding Gilead's treatment options beyond Biktarvy.
GS-1720 FDA clearance enables two parallel wholly-owned once-weekly oral HIV Phase II programs: Berger disclosed that GS-1720, an investigational oral long-acting integrase strand transfer inhibitor (INSTI), has recently received FDA clearance to proceed to further clinical studies. This enables Gilead to initiate two Phase II trials of wholly-owned once-weekly oral regimens: lenacapavir plus GS-3242 (a separate investigational oral INSTI) before year-end, and lenacapavir plus GS-1720 in early 2027. Berger said the company intends to advance the combination with the most compelling profile to Phase III, positioning these programs as potential successors to ISL/LEN — which is partnered with Merck — and as preferred options across both treatment-naive and virally suppressed populations given the well-established safety and resistance profile of INSTI-based backbones.